Analysts Set Transcat, Inc. (NASDAQ:TRNS) Price Target at $114.00

Transcat, Inc. (NASDAQ:TRNS) has been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $112.20.

A number of equities analysts have recently commented on TRNS shares. Lake Street Capital started coverage on shares of Transcat in a report on Thursday. They set a “buy” rating and a $105.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $116.00 target price on shares of Transcat in a report on Wednesday, June 25th. Finally, Wall Street Zen upgraded shares of Transcat from a “sell” rating to a “hold” rating in a report on Wednesday, May 28th.

Hedge Funds Weigh In On Transcat

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Transcat by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,137 shares of the scientific and technical instruments company’s stock worth $543,000 after purchasing an additional 194 shares in the last quarter. Neuberger Berman Group LLC grew its position in Transcat by 1.8% in the 4th quarter. Neuberger Berman Group LLC now owns 873,985 shares of the scientific and technical instruments company’s stock worth $92,415,000 after purchasing an additional 15,723 shares in the last quarter. GAMMA Investing LLC grew its position in Transcat by 10,137.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the scientific and technical instruments company’s stock worth $122,000 after purchasing an additional 1,622 shares in the last quarter. Deutsche Bank AG grew its position in Transcat by 49.9% in the 4th quarter. Deutsche Bank AG now owns 7,833 shares of the scientific and technical instruments company’s stock worth $828,000 after purchasing an additional 2,608 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Transcat by 24.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,029 shares of the scientific and technical instruments company’s stock worth $1,801,000 after purchasing an additional 3,307 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Transcat Stock Performance

Shares of NASDAQ:TRNS opened at $86.59 on Thursday. The company’s 50 day simple moving average is $83.67 and its 200 day simple moving average is $84.13. The stock has a market capitalization of $807.02 million, a price-to-earnings ratio of 55.51 and a beta of 0.73. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.29 and a quick ratio of 1.87. Transcat has a 1 year low of $67.56 and a 1 year high of $147.12.

Transcat (NASDAQ:TRNS) last issued its earnings results on Monday, May 19th. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, missing analysts’ consensus estimates of $0.66 by ($0.02). Transcat had a net margin of 5.21% and a return on equity of 6.47%. The company had revenue of $77.13 million during the quarter, compared to analyst estimates of $76.40 million. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. As a group, research analysts predict that Transcat will post 2.3 EPS for the current fiscal year.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.